<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
     xmlns:dc="http://purl.org/dc/elements/1.1/"
     xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
     xmlns:admin="http://webns.net/mvcb/"
     xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
     xmlns:content="http://purl.org/rss/1.0/modules/content/"
     xmlns:media="http://search.yahoo.com/mrss/">
<channel>
<title>Counterpoint &#45; Md. Mahady Hasan</title>
<link>https://counterpointbd.com/rss/author/md-mahady-hasan</link>
<description>Counterpoint &#45; Md. Mahady Hasan</description>
<dc:language>en</dc:language>
<dc:rights>Copyright 2025 counterpoint&#45; All Rights Reserved.</dc:rights>

<item>
<title>Profits Over Patients</title>
<link>https://counterpointbd.com/profits-over-patients</link>
<guid>https://counterpointbd.com/profits-over-patients</guid>
<description><![CDATA[ If essential medicines remain outside effective price control, public health will depend less on policy -- and more on what patients can afford. For many Bangladeshis, that is not a sustainable equation. ]]></description>
<enclosure url="https://counterpointbd.com/uploads/images/202608/image_870x580_6a782d8d55027.jpg" length="56155" type="image/jpeg"/>
<pubDate>Wed, 12 Aug 2026 13:38:15 +0600</pubDate>
<dc:creator>Md. Mahady Hasan</dc:creator>
<media:keywords>Medicine Price Control</media:keywords>
</item>

</channel>
</rss>